Should T-DXd Move Upfront in Early-Stage HER2+ Breast Cancer?

With historic efficacy in metastatic disease, the next question was inevitable: does T-DXd belong in the early-stage setting?

This clip introduces DESTINY-Breast11 and explores why investigators tested antibody–drug conjugates in high-risk, early-stage HER2-positive breast cancer — and what the early results suggest.